Four Huge Updates: NOHO Signs Letter of Intent for FDA Registered Drug Formulation
http://www.otcmarkets.com/stock/DRNK/news/NOH...64&b=y
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.
For additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink
DD to the DRNK LOI drug by DMR Biologic , LLC (formerly Puramed Biosc.) :
https://www.bizapedia.com/wi/dmr-biologics-llc.html
https://ndclist.com/?s=34331-202-06 (puramed bioscience;
1326 Schofield Avenue
Schofield, WI 54476
thats PMBS http://www.otcmarkets.com/stock/PMBS/profile
looks like they renamed into DMR Biologic, LLC )
Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sec...=8,409,637
NOHO Inks Deal for Nationwide Distribution
https://finance.yahoo.com/news/noho-inks-deal...00865.html
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company"
, announced the following:
The Company is pleased to announce the signing of a national sales and distribution agreement with BNG Enterprises, Inc. ("BNG" , located in Tempe, Arizona (www.bngprodx.com). The agreement provides BNG the exclusive rights to sell the NOHO 2oz Shot throughout its nationwide retail stores as well as online sales through Amazon®.
BNG has been a leading manufacturer in the natural foods and supplements industry for over 20 years. BNG's products can be found in thousands of retailers across the country. Our NOHO 2oz Shot will now be placed into the BNG sales engine, with the ability to be sold in national chains such as GNC and Vitamin Shoppe, in addition to independent smoke shops, vape shops and health stores. BNG's sales force will be putting the Shot into its national distribution in all major markets with concentration in California, New York and Florida.
David Mersky, NOHO's CEO, stated, "NOHO is proud to announce this deal with BNG Enterprises and is excited to begin moving product into retail stores across the country. In addition to its core strength in selling to retail smoke shops and vape stores, where NOHO is a natural fit, BNG also has established relationships with big box retailers, convenience stores and the supermarket space. This deal brings NOHO the ability to manufacture, warehouse and ship product through a well-established sales and distribution partner with a stellar reputation. This is just the beginning of what we envision to be a long-term relationship."
The Company is in the process of moving inventory to BNG for immediate distribution. BNG will also be managing all online sales of NOHO products through Amazon®, taking advantage of a streamlined delivery system with all of the Amazon® Prime and related benefits.
"We are really excited to enter this relationship with BNG. Not only does this put in place a solid structure to handle both retail and online sales, but it offers NOHO a logistical solution to be able to move the product into stores that we did not have before," said Mersky. "In terms of the near future, we are currently in talks with a producer of cutting edge cannabis products to bring into NOHO through acquisition. BNG's targeted distribution in the smoke and vape shop arenas has essentially set the table for us to be able to bring these products to market. I look forward to providing an update on this very soon."
Update 4/26/17 A/S reduced (filed for 4/20/2017 as CEO stated)
https://wyobiz.wy.gov/Business/FilingDetails....1140218168
see Additional Details
see also Update Restated Articles
NOHO, Inc. to Freeze Conversions and Negotiates Debt Buyout
https://finance.yahoo.com/news/noho-inc-freez...00170.html
PHOENIX, AZ--(Marketwired - Apr 24, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company" , announced the following:
The Company has reached an agreement in principle with its 95% majority convertible note holder for a moratorium on conversions, relating to notes issued after March 7, 2015.
In addition to freezing conversions, the Company will maintain its ability to retire the outstanding notes in cash.
Pursuant to the agreement, NOHO will be forming a financial services division wherein a percentage of top line revenues will be allocated toward funding the debt repurchase plan. Details on the new division will be announced prior to May 31, 2017.
If the notes subject to the freeze are not repurchased by the Company, the parties have agreed to a restriction of stock sales, subject to a lockdown and leakout agreement, which is currently being finalized.
David Mersky, NOHO's CEO, stated, "We have come to terms with our majority note holder to freeze conversions, which puts NOHO in a very strong position moving forward with significant developments underway. This is a strong signal of our majority debt holder's confidence in the long term vision we have for the Company. This agreement is also a big win for our shareholders, as we continue to make changes to reduce the outstanding shares and avoid dilution as a priority moving forward."
http://www.otcmarkets.com/stock/DRNK/news/NOH...64&b=y
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.
For additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink
DD to the DRNK LOI drug by DMR Biologic , LLC (formerly Puramed Biosc.) :
https://www.bizapedia.com/wi/dmr-biologics-llc.html
https://ndclist.com/?s=34331-202-06 (puramed bioscience;
1326 Schofield Avenue
Schofield, WI 54476
thats PMBS http://www.otcmarkets.com/stock/PMBS/profile
looks like they renamed into DMR Biologic, LLC )
Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sec...=8,409,637
NOHO Inks Deal for Nationwide Distribution
https://finance.yahoo.com/news/noho-inks-deal...00865.html
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company"
, announced the following: The Company is pleased to announce the signing of a national sales and distribution agreement with BNG Enterprises, Inc. ("BNG"
, located in Tempe, Arizona (www.bngprodx.com). The agreement provides BNG the exclusive rights to sell the NOHO 2oz Shot throughout its nationwide retail stores as well as online sales through Amazon®. BNG has been a leading manufacturer in the natural foods and supplements industry for over 20 years. BNG's products can be found in thousands of retailers across the country. Our NOHO 2oz Shot will now be placed into the BNG sales engine, with the ability to be sold in national chains such as GNC and Vitamin Shoppe, in addition to independent smoke shops, vape shops and health stores. BNG's sales force will be putting the Shot into its national distribution in all major markets with concentration in California, New York and Florida.
David Mersky, NOHO's CEO, stated, "NOHO is proud to announce this deal with BNG Enterprises and is excited to begin moving product into retail stores across the country. In addition to its core strength in selling to retail smoke shops and vape stores, where NOHO is a natural fit, BNG also has established relationships with big box retailers, convenience stores and the supermarket space. This deal brings NOHO the ability to manufacture, warehouse and ship product through a well-established sales and distribution partner with a stellar reputation. This is just the beginning of what we envision to be a long-term relationship."
The Company is in the process of moving inventory to BNG for immediate distribution. BNG will also be managing all online sales of NOHO products through Amazon®, taking advantage of a streamlined delivery system with all of the Amazon® Prime and related benefits.
"We are really excited to enter this relationship with BNG. Not only does this put in place a solid structure to handle both retail and online sales, but it offers NOHO a logistical solution to be able to move the product into stores that we did not have before," said Mersky. "In terms of the near future, we are currently in talks with a producer of cutting edge cannabis products to bring into NOHO through acquisition. BNG's targeted distribution in the smoke and vape shop arenas has essentially set the table for us to be able to bring these products to market. I look forward to providing an update on this very soon."
Update 4/26/17 A/S reduced (filed for 4/20/2017 as CEO stated)
https://wyobiz.wy.gov/Business/FilingDetails....1140218168
see Additional Details
see also Update Restated Articles
NOHO, Inc. to Freeze Conversions and Negotiates Debt Buyout
https://finance.yahoo.com/news/noho-inc-freez...00170.html
PHOENIX, AZ--(Marketwired - Apr 24, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company"
, announced the following: The Company has reached an agreement in principle with its 95% majority convertible note holder for a moratorium on conversions, relating to notes issued after March 7, 2015.
In addition to freezing conversions, the Company will maintain its ability to retire the outstanding notes in cash.
Pursuant to the agreement, NOHO will be forming a financial services division wherein a percentage of top line revenues will be allocated toward funding the debt repurchase plan. Details on the new division will be announced prior to May 31, 2017.
If the notes subject to the freeze are not repurchased by the Company, the parties have agreed to a restriction of stock sales, subject to a lockdown and leakout agreement, which is currently being finalized.
David Mersky, NOHO's CEO, stated, "We have come to terms with our majority note holder to freeze conversions, which puts NOHO in a very strong position moving forward with significant developments underway. This is a strong signal of our majority debt holder's confidence in the long term vision we have for the Company. This agreement is also a big win for our shareholders, as we continue to make changes to reduce the outstanding shares and avoid dilution as a priority moving forward."
